Trial: 201910182

A Phase II Trial of Tisagenlecleucel in First-Line High-Risk (HR) Pediatric and Young Adult Patients With B-cell Acute Lymphoblastic Leukemia (B-ALL) Who are Minimal Residual Disease (MRD) Positive at the End of Consolidation (EOC) Therapy

Phase

II

Principal Investigator

Bhatt, Sima

Disease Site

Lymphoid Leukemia

Learn more about this study at: clinicaltrials.gov